Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study-Reference-Cited by-同舟云学术

Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study

Published:2023-03-29 Issue:5 Volume:64 Page:1005-1016
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Eyre Toby A.¹,Hess Lisa M.²,Sugihara Tomoko³,He Dan³,Khanal Manoj²,Pagel John M.⁴,Walgren Richard A.⁴,B. Abada Paolo⁴,Konig Heiko⁴,Roeker Lindsey E.⁵,Mato Anthony⁵

Affiliation:

1. Oxford Cancer and Hematology Centre, Oxford University NHS Foundation Trust, Oxford, UK

2. Eli Lilly and Company, Indianapolis, IN, USA

3. Syneos Health, Inc, Morrisville, NC, USA

4. Loxo@Lilly, Indianapolis, IN, USA

5. Memorial Sloan Kettering Cancer Center, New York, NY, USA

Funder

Eli Lilly and Company

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2190436

Reference21 articles.

1. The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia

2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

3. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

4. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

5. FDA [Internet]. Drugs@FDA: FDA-Approved Drugs; Calquence 2019. Available from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210259.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study;Leukemia & Lymphoma;2024-05-02

2. CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA;Mediterranean Journal of Hematology and Infectious Diseases;2024-04-30

3. Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon;Blood Advances;2024-03-15

4. Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL);Clinical Lymphoma Myeloma and Leukemia;2024-02

5. Pirtobrutinib <i>versus</i> venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison;Haematologica;2023-11-30